VanEck Biotech ETF BBH

El Fondo busca replicar el precio y rendimiento de la Market Vectors US Listed Biotech 25 Index. El índice está compuesto por acciones comunes y recibos de depósito de empresas estadounidenses listadas en bolsa en el sector de la biotecnología.

Con 4 acciones de BBH (USD 962,20) habrías recibido USD 3,84 en dividendos en los últimos 12 meses.

• Zacks Investment Research 21 sept

  Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate

  Biotech companies are increasingly directing capital toward oncology therapeutics, with over $3.9 billion of venture capital flowing into cancer and immunology drug developers in H1 2026. The global oncology drugs market is projected to grow from $256.5 billion in 2025 to nearly $700 billion by 2034, prompting investors to consider biotech ETFs for diversified exposure to this growth opportunity rather than individual stocks.

  

• Zacks Investment Research 16 sept

  Should You Invest in the VanEck Biotech ETF (BBH)?

  The VanEck Biotech ETF (BBH) offers low-cost exposure to the biotech sector with a 0.35% expense ratio and $462.7 million in assets. The fund tracks the MVIS US Listed Biotech 25 Index and holds 26 companies with top holdings including Amgen, Gilead Sciences, and Vertex Pharmaceuticals. BBH has returned 21.89% year-to-date and 39.46% over the past year, but carries higher risk with a beta of 0.70 and 19.89% standard deviation. The fund received a Zacks ETF Rank of 2 (Buy).

  

• The Motley Fool 28 ago

  Which Healthcare ETF Offers the Better Growth Outlook: VanEck Biotech or Invesco Pharmaceuticals?

  The article compares two healthcare ETFs: VanEck Biotech ETF (BBH) with a lower 0.35% expense ratio and concentrated biotech focus, versus Invesco Pharmaceuticals ETF (PJP) with higher dividend yield and broader pharma exposure. Despite PJP's superior 5-year performance and lower volatility, the article concludes BBH is the better buy based on recent outperformance, though both funds offer targeted healthcare sector exposure with different risk-return profiles.

  

• The Motley Fool 22 ago

  Which Biotech ETF Is a Better Buy: Concentrated Bet or Broad Basket?

  Invesco Nasdaq Biotechnology ETF (IBBQ) emerges as the better choice over VanEck Biotech ETF (BBH) for most investors. IBBQ offers broader diversification with 251 holdings, lower fees (0.19% vs 0.35%), higher dividend yield (0.8% vs 0.4%), and superior 5-year returns ($1,338 vs $1,061 on $1,000 invested). While BBH's concentrated 25-stock portfolio provides focused exposure to biotech leaders, it carries higher single-company risk without compensating benefits.

  

• The Motley Fool 5 ago

  State Street XLV vs VanEck BBH: Which Healthcare ETF Is the Better Buy in 2026?

  State Street's XLV healthcare ETF offers broader exposure with lower costs (0.08% expense ratio) and higher dividend yield (1.6%), delivering 30% more growth over five years with lower volatility. VanEck's BBH biotech ETF provides concentrated exposure to 25 biotech stocks with higher recent returns but greater risk, making XLV the better choice for long-term investors seeking defensive characteristics.